AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01532700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab with GSK2110183
Description: * GSK2110183 125mg OD continuously~* Ofatumumab 300mg IV first dose, 2000mg weekly x 7 doses, then 2000mg monthly x 4 doses
Study NCT03127215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib 150 mg tablet
Study NCT03127215 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Physician's choice
Description: treatment according to current guidelines
Study NCT03127215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Trabectedin 1.1mg/m² infusional solution
Study NCT02819648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: 40 mg prednisolone (two tablets Prednisolone 20 mg, Aventis Intercontinental, Paris, France)
Study NCT01894230 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SLCO1B1*5 allele testing, results reported at randomization
Description: Genetic testing for SLCO1B1\*5 allele and reporting of results to patient and provider at randomization
Study NCT01894230 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: SLCO1B1*5 allele testing, results reported at end of study
Description: Genetic testing for SLCO1B1\*5 allele and reporting of results to patient and provider at end of study
Study NCT01894230 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic testing for SLCO1B1*5 allele
Description: Blood test for SLCO1B1\*5 allele
Study NCT01894230 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Genetic testing for SLCO1B1*5 allele
Description: Blood test for SLCO1B1\*5 allele
Study NCT01758406 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intracoronary injection
Description: stem cell transplantation
Study NCT01758406 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Intracoronary injection of Placebo
Description: Injection of Placebo via coronary arteries in patients with heart failure.
Study NCT00412204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tiotropium bromide
Description: Subjects will be randomized to treatment with tiotropium or placebo. Double-blind medication will be dispensed in HandiHalers to be taken once daily in the morning for 22 days.
Study NCT00412204 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized to treatment with tiotropium or placebo. Double-blind medication will be dispensed in HandiHalers to be taken once daily in the morning for 22 days.
Study NCT01149434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JI-101
Description: JI-101 inhibits angiogenesis, and subsequently tumor growth, by inhibiting three receptor tyrosine kinases: VEGF Receptor Type 2 (VEGFR 2), platelet derived growth factor receptor beta (PDGFR β and Ephrin B4 (EphB4). JI-101 selectively inhibits kinases critical for all three stages of tumor angiogenesis.
Study NCT01149434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus is a signal transduction inhibitor that selectively inhibits mTOR (mammalian target of rapamycin), a key and highly conserved serine-threonine kinase, that is present in all cells and is a central regulator of protein synthesis and ultimately cell growth, cell proliferation, angiogenesis, and cell survival. mTOR is the only currently known target of everolimus (1).
Study NCT01848210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coumarin/troxerutin
Description: Coumarin + troxerutin fixed-dose combination tablets
Study NCT01848210 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Coumarin + troxerutin placebo-matching tablets
Study NCT02577068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nefopam
Description: Patients undergoing thyroidectomy receive medications depending on the group allocation 30minutes prior to the surgery end; Nefopam 20mg, Propacetamol 2g, and Nefopam 20mg+Propacetamol 2g. In addition, patients will take the same medication every six hours during POD 1.
Study NCT02577068 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nefopam
Description: Patients undergoing thyroidectomy receive medications depending on the group allocation 30minutes prior to the surgery end; Nefopam 20mg, Propacetamol 2g, and Nefopam 20mg+Propacetamol 2g. In addition, patients will take the same medication every six hours during POD 1.
Study NCT02577068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propacetamol
Description: Patients undergoing thyroidectomy receive medications depending on the group allocation 30minutes prior to the surgery end; Nefopam 20mg, Propacetamol 2g, and Nefopam 20mg+Propacetamol 2g. In addition, patients will take the same medication every six hours during POD 1.
Study NCT02577068 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propacetamol
Description: Patients undergoing thyroidectomy receive medications depending on the group allocation 30minutes prior to the surgery end; Nefopam 20mg, Propacetamol 2g, and Nefopam 20mg+Propacetamol 2g. In addition, patients will take the same medication every six hours during POD 1.
Study NCT03562949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Product
Description: Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg
Study NCT02819648 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Milk Tablet
Study NCT02064439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 59-7939
Description: 10 mg tablet once daily for 12 months
Study NCT03562949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference Product
Description: QVAR® 40 mcg (Beclomethasone Dipropionate HFA)
Study NCT03562949 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Product
Study NCT01245842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand exercise program
Description: Hand exercise program three times/week for 12 weeks. In total four group sessions, otherwise home based. Weekly telephone calls from experienced physiotherapist/occupational therapist addressing adjustments of the exercise program and encouragement of program adherence.
Study NCT02824640 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Navigation
Description: The study will follow a PN model (Check Hep C) developed by NYCDOH in collaboration with Montefiore and the community. HCV PNs will provide the following interventions to those randomized to the PN arm: coordination of HCV treatment; health promotion; assisting patients to overcome barriers; and psychosocial support.
Study NCT02824640 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: modified Directly Observed Therapy
Description: Subjects will be observed taking medications, a minimum of 5 times a week for those enrolled in the OAT setting, and a minimum of 3 times a week for those enrolled in the community health clinic setting.
Study NCT00333177 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy behavior training (HBT)
Description: Healthy behavior training includes group skills training in nutrition, exercise, and relaxation.
Study NCT03555994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382
Description: MEDI0382 administered subcutaneously
Study NCT03555994 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously
Study NCT03555994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Liraglutide administered subcutaneously
Study NCT06063551 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Testicular Biopsy
Description: Testicular biopsy for clinical storage and laboratory research.
Study NCT03774121 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoneurolysis
Description: A cryoprobe will be inserted percutaneously and freeze the target nerves (infrapatellar branch of the saphenous nerve \& anterior femoral cutaneous nerve) guided by ultrasound visualization.
Study NCT03774121 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular exercise (GLA:D)
Description: The GLA:D program, is a standard education and exercise program for patients with osteoarthritis in Denmark. The program is performed in groups and with the supervision of an experienced physiotherapist specialized in training of musculoskeletal disorders.
Study NCT03774121 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Neuromuscular exercise (GLA:D)
Description: The GLA:D program, is a standard education and exercise program for patients with osteoarthritis in Denmark. The program is performed in groups and with the supervision of an experienced physiotherapist specialized in training of musculoskeletal disorders.
Study NCT03774121 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The sham intervention includes a similar procedure but without freezing temperatures.
Study NCT03559556 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CT angiography
Description: CT angiography uses a CT scanner to produce detailed images of both blood vessels and tissues in various parts of the body. An iodine-rich contrast material (dye) is usually injected through a small catheter placed in a vein of the arm.
Study NCT03141970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone for 12 weeks as follows 30 mg/m2 on alternate days for 4 weeks 20 mg/m2 on alternate days for 4 weeks 10 mg/m2 on alternate days for 4 weeks
Study NCT00153933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given intravenously on days 1, 2, 8, 11 of each 21-day cycle. Participants can remain on study treatment as long as their disease doesn't worsen and they don't experience any serious side effects.
Study NCT00153933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-5013
Description: Orally on days 1-14 of each 21-day cycle. Participants can remain on study treatment as long as their disease doesn't worsen and they don't experience any serious side effects.
Study NCT02113878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: BKM120 is a potent and highly specific oral pan-class I PI3K inhibitor.
Study NCT02113878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin is a chemotherapy drug
Study NCT02113878 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT)
Description: IMRT is the medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells
Study NCT02064439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 59-7939
Description: 20 mg tablet once daily for 12 months
Study NCT02064439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASA
Description: 100 mg tablet once daily for 12 months
Study NCT02433288 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Smart phone based patient support tool
Description: The smart phone application used on the patients' smart phones will contain both the patient support tool and the questions for the clinical evaluation in the form of the Rosuvastatin Adherence questionnaire (RAQ), Beliefs about Medicine Questionnaire - General (BMQ-G), (Horne, 1999) and a Lifestyle questionnaire (LSQ) on disease understanding, lifestyle and treatment awareness. Patients in the Active group will also receive feedback on their daily rosuvastatin treatment as entered in the patient support tool.
Study NCT02433288 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control application: only for data collection
Description: the patients will have no access to the smart phone-based patient support tool. However, a smart phone application will be used to prompt patients with the questions for the clinical evaluation (RAQ, BMQ-G and LSQ).
Study NCT02526927 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HR-pQCT
Description: The Xtrem CT scanco device is a HR-pQCT used for 3D bone measurements at the tibia and the radius levels in human
Study NCT02526927 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DEXA
Description: The Lunar DEXA (Dual Energy X-ray Absorptiometry) is a third generation multi-captor DEXA device that allows short duration measurements (\< 15 min). It measures Bone Mineral Density at the spine (L1-L4) and the femoral neck
Study NCT02526927 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samples
Study NCT04181567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroconvulsive therapy
Description: electroconvulsive therapy 2 times weekly
Study NCT04181567 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: electroconvulsive therapy
Description: electroconvulsive therapy 2 times weekly
Study NCT04181567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: agomelatine
Description: agomelatine
Study NCT04181567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT02549690 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone gel
Description: Apply 10mg testosterone gel to the abdomen and rub on with one finger, once a day, in the morning, then allow sites to dry and cover with clothing. Continue the treatment for 6-8 weeks until next IVF treatment.
Study NCT02549690 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DHEA
Description: Take DHEA 25mg tablet orally, three times per day. Continue the treatment for 6-8 weeks, until next IVF treatment.
Study NCT02891031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rhus (Somagh)
Description: 500 mg twice daily after meal for 6 weeks
Study NCT02891031 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 mg twice daily after meal for 6 weeks
Study NCT00339014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zonisamide CR and Bupropion SR
Description: Zonisamide SR and Bupropion SR
Study NCT00339014 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical placebo
Study NCT00333177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone, administered orally (Oral Ris)
Description: Oral risperidone at dosage judged optimal by treating psychiatrist
Study NCT00333177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone, administered orally (Oral Ris)
Description: Oral risperidone at dosage judged optimal by treating psychiatrist
Study NCT00333177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone, administered via injection (RLAI)
Description: Risperidone in injectable form every 2 weeks, starting with 25 mg and adjusted as needed
Study NCT00333177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone, administered via injection (RLAI)
Description: Risperidone in injectable form every 2 weeks, starting with 25 mg and adjusted as needed
Study NCT03376048 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wound infiltration plus TAP
Description: 1. TAP block: At the beginning of the main surgical procedure the surgeon will perform a TAP with ropivacaine infiltration, bilaterally in the anterior axillary line, between the costal margin and iliac crest in the intermuscular plane between the internal oblique and transversus abdominis muscles, the anesthesiologist under ultrasound guidance, the surgeon under laparoscopic guidance (two pops technique).~2. Wound infiltration : Wound infiltration of ropivacaine will be performed by the surgeon before skin incision.
Study NCT03376048 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound infiltration
Description: Wound infiltration of ropivacaine will be performed by the surgeon before skin incision.
Study NCT02301130 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mogamulizumab
Description: Mogamulizumab will be administered intravenously (IV).
Study NCT02301130 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4736 (Durvalumab)
Description: MEDI4736 will be administered intravenously (IV).
Study NCT02301130 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tremelimumab
Description: Tremelimumab will be administered intravenously (IV).
Study NCT03633617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Solution for injection administered subcutaneously
Study NCT04372992 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Timing of stoma closure
Description: Defining the best timing of stoma closure in relation to adjuvant therapy compliance
Study NCT04372992 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Timing of stoma closure
Description: Defining the best timing of stoma closure in relation to adjuvant therapy compliance
Study NCT01151254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoflurane/sevoflurane
Description: Volatile for sedation in the CVICU while intubated
Study NCT01151254 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol for sedation in the CVICU
Study NCT02004613 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine
Study NCT01241838 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker
Description: Routine postoperative temporary pacemaker Rate change of 65-80-95-110-125 beats/second in random order at day 3-4 after operation
Study NCT01241838 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Pacemaker
Description: Routine postoperative temporary pacemaker Rate change of 65-80-95-110-125 beats/second in random order at day 3-4 after operation
Study NCT02004613 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline administration matching dexmedetomidine rate of infusion
Study NCT01205412 — intervention group
Intervention type: PROCEDURE
Intervention: Endocervical samples
Description: Endocervical samples collection during routine gynaecological examinations
Study NCT02496208 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsies
Study NCT02496208 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study NCT02496208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO
Study NCT02496208 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT04582357 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity program
Description: The physical activity program is a suite of several exercises which intend to improve muscular mass of targeted muscles.
Study NCT02496208 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiography
Study NCT02496208 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT02496208 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT02496208 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT03633617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo
Study NCT04225065 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: Chlorhexidine prep prior to surgery
Study NCT04225065 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Betadine
Description: Betadine prep prior to surgery
Study NCT03252717 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Pre-treatment blood samples will be collected for downstream analyses:~* Three 6 ml EDTA samples for proteomic and genomic work package~* One 6 ml dry sample for auto-antibodies analysis in the immunology work package~* Two 4 ml EDTA samples for DNA extraction in the immunology work package~* Two 2.5 ml PAX Gene sample for RNA extraction in the immunology work package and the non-irradiated control in the genomic work package
Study NCT03869294 — intervention group
Intervention type: DRUG
Intervention: GS
Description: Gemcitabine plus S-1 (GS) was used to treat advanced pancreatic cancer
Study NCT02065986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada (once daily tablet containing 300mg tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC)
Study NCT02065986 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Truvada (once daily tablet containing 300mg tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC)
Study NCT02971137 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation plus CBI
Description: proactive tele-health intervention combining evidence-based smoking cessation counseling augmented with behavioral approaches for coping with pain
Study NCT02971137 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation Standard
Description: standard telephone-based smoking cessation intervention
Study NCT02088086 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BMI screening
Description: Students in grades 3-8 will have their heights and weights measured annually at school and their BMIs calculated.